ABT

Abbott Laboratories 2005 Annual Report (10-K) Summary

Business Context and Reporting Period

This Form 10-K covers the fiscal year ended December 31, 2005. Abbott Laboratories is a global healthcare company organized into four reportable segments: Pharmaceutical Products, Diagnostic Products, Ross Products (nutritionals), and International. The company also holds a 50% interest in TAP Pharmaceutical Products Inc. In 2004, Abbott spun off its hospital products business into Hospira, Inc., which is reported as discontinued operations. In early 2006, Abbott announced an agreement to acquire Guidant's vascular intervention businesses contingent on Boston Scientific's acquisition of Guidant.

Key Financial Metrics

Research & Development: $1.82 billion in 2005 (7.3% increase from 2004).
Dividends: $1.10 per share declared in 2005.

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 13.5% to $22.3 billion, driven by a 12.1% volume increase and favorable foreign exchange rates (1.3%).
• Product Performance: Worldwide sales of HUMIRA (rheumatoid arthritis) grew to $1.4 billion in 2005 from $852 million in 2004. Conversely, U.S. sales of Synthroid declined 22% due to generic competition.
• Margin Compression: Gross profit margin decreased to 52.4% from 54.9% in 2004. This was primarily due to an unfavorable product mix from increased sales of lower-margin Boehringer Ingelheim products ($2.3 billion in sales) and restructuring charges.
• Restructuring: Abbott recorded $256 million in pretax restructuring charges in 2005 related to global manufacturing realignment and asset impairments.
• Tax Rate: The effective tax rate rose to 27.0% in 2005 from 23.0% in 2004, largely due to a $245 million tax expense associated with the repatriation of foreign earnings under the American Jobs Creation Act of 2004.

Guidance, Outlook, and Risks

• 2006 Outlook: Abbott expects an effective tax rate between 23.5% and 24.0%. The company plans to launch new indications for HUMIRA and focus on market support for Synthroid and sevoflurane amidst generic competition.
• Acquisitions: Pending acquisition of Guidant's vascular business for approximately $4.1 billion plus milestones. Abbott also agreed to provide a $900 million loan to Boston Scientific.
• Accounting Changes: In 2006, Abbott will adopt SFAS No. 123(R), requiring fair value expensing of stock options. This is estimated to reduce diluted EPS by approximately $0.15 in 2006.
• Patent Expirations: Significant risks include the expiration of the U.S. composition of matter patent for Depakote (2008) and clarithromycin (expired 2005, though non-composition patents remain). Generic competition for sevoflurane began in December 2005.
• Legal Proceedings: Abbott faces numerous lawsuits regarding OxyContin (indemnified by Purdue Pharma), Meridia (sibutramine), and antitrust claims related to fenofibrate and pharmaceutical pricing. Management believes reserves of $35 million are adequate and outcomes will not be materially adverse.

Investor Verification Checklist

• HUMIRA Growth: Verify the sustainability of HUMIRA sales growth ($1.4B in 2005) as a primary driver of future profitability.
• Generic Impact: Assess the long-term revenue erosion from Synthroid and clarithromycin due to generic entry and the effectiveness of Abbott's non-composition patent defenses.
• Restructuring Costs: Monitor the $150 million in expected future restructuring costs and the timeline for manufacturing realignment.
• Stock Compensation Impact: Confirm the actual EPS impact of the 2006 adoption of SFAS 123(R) on stock option expensing.
• Guidant Acquisition: Track regulatory approval status and integration plans for the Guidant vascular business acquisition.
• Rebate Accruals: Review the adequacy of sales rebate reserves, which totaled approximately $1.0 billion across major categories (Medicaid, WIC, PBM, Wholesaler).